On October 18, 2007, FDA approved expanding the age range for Menactra, a bacterial meningitis vaccine, to include children ages 2 to 10 years. The vaccine was first approved by FDA in January 2005 for people ages 11 to 55 years. Until now, Menomune was the only meningococcal vaccine available in the United States for use in children ages 2 and older. Menactra and Menomune are manufactured by sanofi pasteur Inc. of Swiftwater, Pa.